PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17145602-8	2006	Current clinical peptide vaccination trials targeting different epitopes of the Wilms" tumor gene 1 (WT1), the proteinase-3 derived epitope peptide (PR1) and the receptor for hyaluronic acid mediated motility (RHAMM/CD168)-derived epitope R3 are reviewed, and perspectives but also limitations of immunotherapeutic approaches for AML patients are discussed.	Hyaluronic Acid	175-190	transmembrane protein 37	Homo sapiens	149-152